ETX-101

Diabetes’s-associated gastroparesis and idiopathic gastroparesis (of unknown cause) are neuropathies of the stomach muscles exhibiting loss of nitric oxide signaling “relax message” that prevent normal emptying of the stomach. This condition seriously reduces the patient’s quality of life and increases both morbidity and mortality

ETX-101 is the only drug currently in development that restores native nitric oxide signaling and should enjoy rapid adoption in this underserved indication

Learn More About ETX-101

ETX-202

Crohn’s Disease is a relapsing inflammation of the ileum and colon that leads to ulceration and progressive intestinal damage 

ETX-202 is an anti-inflammatory, oral, small molecule

ETX-202 is expected to be much safer than other drugs

Currently the leading therapeutics for moderate to severe Crohn’s Disease require I.V. administration and carry double black box warnings for cancer and infectious disease risks

Whereas, ETX-202 is a self-administered daily pill

Learn More About ETX-202

ETX-301

Diabetes’s-associated gastroparesis and idiopathic gastroparesis (of unknown cause) are neuropathies of the stomach muscles exhibiting loss of nitric oxide signaling “relax message” that prevent normal emptying of the stomach. This condition seriously reduces the patient’s quality of life and increases both morbidity and mortality

ETX pre-clinical compound (ETX-301) is in development for severe gastroparesis where the patients have completely lost their natural ability to generate nitric oxide

Learn More About ETX-301

ETX Pharma, Inc - Real Solutions for Patients

  • A clinical stage pharmaceutical company with a pipeline of disease modifying gastrointestinal (GI) drugs
  • Developing de-risked oral drugs to treat diabetic and idiopathic Gastroparesis and Crohn’s Disease with early out-licensing opportunities to offset dilutive equity financings
  • ETX-101 & ETX-301 treat gastroparesis, a serious disease for which over 1.5M patients currently have no effective treatments are both breakthrough mode of action drugs treating the root cause of gastroparesis
  • ETX-202 treats Crohns Disease and is planned for out-license in 2021
  • ETX-302 is a hemostat device based on ETX-031 technology and planned for outlicense in 2019
4825-5

Next Steps...

ETX is happy to answer all your questions regarding our drug programs,

ETX does not and cannot provide medical advice regarding treatment for any disease.

Please contact ETX  for further information...